R&D Cost Estimate Should Be Studied By FDA, Rep. Brown Tells Commissioner
Executive Summary
FDA should gather its own data on the cost of drug development rather than repeat the industry estimate of $800 mil. per new molecular entity, Rep. Sherrod Brown (D-Ohio) told an IIR conference on generic drugs Oct. 1 in Washington, D.C